JW Pharmaceutical Corporation (KRX:001065)

JW Pharmaceutical Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	11,062	10,430	15,909	33,898	33,366	10,451
Short-Term Investments	23,953	22,121	48,288	53,781	32,300	44,840
Trading Asset Securities	37,513	-	30,000	62,000	-	-
Cash & Short-Term Investments	72,528	32,551	94,196	149,678	65,666	55,291
Cash Growth	-32.66%	-65.44%	-37.07%	127.94%	18.76%	32.07%
Accounts Receivable	125,286	135,503	159,378	147,523	151,780	122,833
Other Receivables	-	3,571	5,644	5,962	5,499	5,296
Receivables	125,286	155,763	173,521	156,362	187,379	128,129
Inventory	119,463	111,733	106,091	111,668	102,528	101,198
Prepaid Expenses	-	1,883	1,848	1,774	5,152	3,434
Other Current Assets	7,547	4,484	2,434	5,975	5,727	11,276
Total Current Assets	324,825	306,413	378,091	425,457	366,452	299,329
Property, Plant & Equipment	166,318	172,291	155,724	123,048	118,392	185,572
Long-Term Investments	35,841	63,801	36,995	33,957	98,884	20,304
Goodwill	-	-	1,404	-	-	-
Other Intangible Assets	10,383	10,878	12,248	11,750	12,773	12,308
Long-Term Deferred Tax Assets	13,676	13,569	20,623	21,811	20,802	17,980
Long-Term Deferred Charges	36,774	29,958	16,704	4,516	8,700	5,358
Other Long-Term Assets	2,262	7,688	7,746	269.55	4,050	5,235
Total Assets	590,079	604,599	645,039	627,973	633,053	549,085
Accounts Payable	-	59,613	73,847	82,908	51,643	47,885
Accrued Expenses	-	22,204	14,495	12,472	10,343	4,992
Short-Term Debt	41,300	31,400	72,968	46,000	81,823	70,000
Current Portion of Long-Term Debt	25,102	10,000	40,166	160,440	39,977	36,466
Current Portion of Leases	4,492	4,352	4,270	1,253	1,274	849.5
Current Income Taxes Payable	11,131	7,794	11,114	10,153	24,877	326.34
Current Unearned Revenue	-	159.58	159.58	153.65	551.41	-
Other Current Liabilities	148,428	73,092	69,907	66,752	72,188	74,228
Total Current Liabilities	230,454	208,615	286,927	380,131	282,678	234,748
Long-Term Debt	-	25,102	30,000	-	120,744	73,585
Long-Term Leases	19,836	20,872	22,876	1,849	1,326	1,320
Long-Term Unearned Revenue	-	1,162	1,317	-	-	-
Long-Term Deferred Tax Liabilities	1,209	1,166	1,276	1,399	-	-
Other Long-Term Liabilities	5,929	12,304	26,882	11,520	17,364	4,994
Total Liabilities	266,803	275,112	379,598	402,214	444,514	341,618
Common Stock	62,253	62,253	61,100	59,418	57,202	55,616
Additional Paid-In Capital	68,321	68,321	69,475	71,063	63,334	64,522
Retained Earnings	168,660	164,123	113,029	89,130	58,595	65,084
Treasury Stock	-21,616	-12,076	-11,325	-11,065	-10,783	-10,371
Comprehensive Income & Other	45,657	46,865	33,162	31,808	32,847	32,640
Total Common Equity	323,276	329,487	265,440	240,354	201,195	207,491
Minority Interest	0	0	0	-14,595	-12,655	-24.04
Shareholders' Equity	323,276	329,487	265,440	225,759	188,540	207,467
Total Liabilities & Equity	590,079	604,599	645,039	627,973	633,053	549,085
Total Debt	90,730	91,726	170,280	209,542	245,145	182,220
Net Cash (Debt)	-18,202	-59,175	-76,084	-59,864	-179,479	-126,929
Net Cash Per Share	-784.03	-2537.03	-3196.37	-2577.51	-7733.47	-5466.27
Filing Date Shares Outstanding	22.89	23.31	22.54	22.34	22.35	22.36
Total Common Shares Outstanding	22.89	23.31	23.33	23.34	23.21	23.22
Working Capital	94,371	97,798	91,164	45,326	83,774	64,581
Book Value Per Share	14124.92	14136.82	11375.92	10299.98	8669.19	8935.72
Tangible Book Value	312,893	318,608	251,788	228,604	188,422	195,183
Tangible Book Value Per Share	13671.23	13670.08	10790.83	9796.44	8118.81	8405.66
Land	44,536	44,536	26,555	22,178	22,178	71,406
Buildings	70,453	120,046	112,052	110,929	110,161	136,003
Machinery	21,738	173,804	169,111	158,179	151,192	147,213
Construction In Progress	3,199	3,588	6,064	8,128	849.45	4,075

Source: S&P Global Market Intelligence. Standard template. Financial Sources.